Full-Time

Senior Opto-Mechanical Engineer

Intuitive Surgical

Intuitive Surgical

10,001+ employees

Manufactures robotic surgical systems and services

No salary listed

Sunnyvale, CA, USA

In Person

Preference for candidates not residing in AL, AR, DE, FL, IN, IA, LA, MD, MS, MO, OK, PA, SC, or TN.

Bachelor's, Master's

Category
Mechanical Engineering
Required Skills
CAD
GD&T
Data Analysis

Get referred to Intuitive Surgical

See people who can refer or advise you

Requirements
  • Skill in opto-mechanical design of free-space optical systems for alignment and stability
  • Skill in the use of 3D CAD modeling and generating 2D CAD part drawings and design specifications
  • Skill in GD&T tolerance analysis
  • Experience initiating and executing design changes with rigorous design control requirements
  • Experience with kinematic mounting principles for precision optical components
  • Ability to collaborate with manufacturing and suppliers to achieve cost effective and manufacturable designs
  • Knowledge of material selection and properties including metal, glass, plastic, adhesives and coatings
  • Knowledge of manufacturing processes, process controls, design of experiments (DOE s) and capability analysis
  • Understanding of measurement capability and control
  • Hands on experience with developing and performing engineering tests including formal design verification including fixture design, data collection, analysis and reporting
  • Excellent communication and documentation skills suitable for a regulated environment
  • Effective collaboration with cross functional teams and suppliers
  • BS or MS in Mechanical Engineering or Opto-Mechanical Engineering or closely related field and 5-10 years work experience
Responsibilities
  • Evaluate proposed changes to the dV5 3D Surgical Viewer opto-mechanical design based on input from users, manufacturing, supply chain and post sales surveillance including modeling, testing and other technical analysis
  • Execute select design changes within rigorous design control requirement including modification of risk analysis, models, drawings and specifications
  • Perform design verification testing and coordinate with responsible functions for design validation when needed
  • Collaborate closely with supply chain and manufacturing to ensure manufacturability, including identifying and researching new vendors/processes
  • Perform advanced troubleshooting and failure analysis of failures
  • Collaborate with cross-functional teams affected by changes
Desired Qualifications
  • Experience with medical device design and applicable regulatory requirements
  • Experience with finite element analysis (FEA) for structural, thermal and optical performance
  • Experience with characterizing optical system performance, image quality and factors affecting human visual perception
  • Solidworks, Matlab, Ansys, Zemax and Windchill experience
  • Experience with optical design and modeling
  • Familiarity with electromechanical design, PCBAs, components and flexible circuits

Intuitive Surgical designs, manufactures, and sells robotic surgical systems and provides related services and accessories for minimally invasive surgery. The core product helps surgeons perform operations with enhanced precision by guiding robotic arms controlled from a console, allowing procedures to be done through small incisions. Instruments and consumables are used with the systems and are supported by service contracts, creating a recurring revenue stream. Compared to competitors, Intuitive has a large installed base and focuses specifically on robotic-assisted surgery, combining devices, disposable instruments, and ongoing services to support hospitals and surgical centers. Its goal is to improve patient outcomes by enabling safer, less invasive procedures while expanding the use and capabilities of robotic surgery for more procedures and providers.

Company Size

10,001+

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

1995

Get referred to Intuitive Surgical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $2.89 billion, up 19%, with 70% gross margin.
  • Europe direct operations started March 2, 2026, adding Italy, Spain, Portugal, and Malta.
  • Ion procedures grew 36% in Q2 2026, expanding beyond da Vinci dependence.

What critics are saying

  • FDA posted a Class II da Vinci 5 recall on February 18, 2026.
  • Surgical Instrument Service and the FTC pressed Ninth Circuit antitrust claims on June 25, 2026.
  • US da Vinci growth slowed to 12% in Q2 2026, threatening premium pricing.

What makes Intuitive Surgical unique

  • Da Vinci 5 cleared for cardiac procedures on January 26, 2026.
  • Intuitive owns 11,710 da Vinci and 1,096 Ion systems, creating switching costs.
  • July 23, 2026 AI platform leverages 20 million procedures, unmatched surgical data scale.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 8th, 2026
Medtronic and Intuitive Surgical lag market amid sector weakness

Medtronic and Intuitive Surgical, two medical device leaders, have underperformed this year due to sector weakness and company-specific challenges. However, both show potential for recovery. Medtronic's fourth-quarter revenue rose 9.9% to $9.8 billion, though adjusted earnings per share fell 4.3% to $1.55 due to higher costs, including tariffs. The company posted its highest annual revenue growth in a decade, driven partly by its Pulse Field Ablation franchise. Medtronic recently received FDA clearance for its Hugo robotic-assisted surgery system for urologic procedures, positioning it to compete in the underpenetrated robotic surgery market. The company plans to spin off its lower-margin diabetes care division, which should improve margins. With a 3.4% forward dividend yield and 49 consecutive years of payout increases, Medtronic appeals to income-focused investors.

Yahoo Finance
Jul 29th, 2026
Intuitive Surgical stock falls 27% despite 31% operating margin and strong da Vinci system sales

Intuitive Surgical's stock has fallen 27% over the past twelve months, now trading 41% below its two-year high. The robotic surgery pioneer trades at 40.8 times earnings, the highest valuation in its sector. The company maintains a 31% operating margin, outpacing Johnson & Johnson's 27% and Medtronic's 18.8%. Revenue grew 21% over the last twelve months. The firm placed 468 da Vinci systems in the most recent quarter, an 18% increase year-over-year, driven by demand for its new da Vinci 5 platform. However, US procedure growth slowed to 12%, compared to 15% worldwide growth. Management attributed the slowdown to changes in patient coverage and premium dynamics causing treatment deferrals.

Yahoo Finance
Jul 20th, 2026
Intuitive Surgical shares drop 14% despite $2.89B revenue as US procedure growth slows to 12%

Intuitive Surgical reported second-quarter revenue of $2.89 billion, up 19% year-on-year and beating Wall Street estimates. Despite this, shares fell 14.1% to a new 52-week low on Friday. The drop followed concerns about slowing US procedure volumes. Whilst global procedures grew 16%, growth for da Vinci systems in the critical US market moderated to 12%. Management noted that changes in patient coverage may be affecting demand for elective procedures. Paradoxically, capital equipment sales remained strong, with 468 da Vinci systems placed in the quarter, up 18% year-on-year. US placements jumped 24%, driven by the new da Vinci 5 platform. Management also detailed plans for an extended use programme launching in 2027, aimed at reducing costs but potentially impacting high-margin recurring revenue.

Yahoo Finance
Jul 16th, 2026
Intuitive Surgical Q2 revenue climbs 19% to $2.89B as procedures grow 16% globally

Intuitive Surgical reported strong Q2 results, with revenue up 19% year-over-year to $2.89 billion and non-GAAP earnings per share rising 28% to $2.80. Recurring revenue accounted for 85% of total sales. Total procedures increased 16%, driven by 15% growth in da Vinci procedures and 36% growth in Ion procedures. Whilst US growth slowed, international da Vinci procedures rose 20%, expanding across Europe and Asia. The company maintained its 2026 procedure outlook, keeping da Vinci procedure growth guidance at 13.5% to 15.5% whilst raising its non-GAAP gross margin forecast to 68% to 69%. Management highlighted continued demand for newer platforms including da Vinci 5, SP and Ion. The installed base grew to nearly 13,000 systems worldwide.

Yahoo Finance
Jul 16th, 2026
Intuitive Surgical beats Q2 revenue estimates with $2.89B but shares fall on surgery volume concerns

Intuitive Surgical reported second-quarter revenue of $2.89 billion, up 18.5% year on year and beating Wall Street estimates of $2.82 billion. The medical technology company's non-GAAP profit of $2.80 per share exceeded analyst expectations by 11.9%. Despite the strong results, the stock declined. The drop was attributed to recent declines in overall surgery volumes reported by major healthcare providers and a Class II recall of certain da Vinci surgical components. Operating margin improved to 33.6%, up from 30.5% in the same quarter last year. Analysts expect revenue to grow 12.5% over the next 12 months, representing a deceleration from recent growth rates. The company has demonstrated solid long-term performance, with 16.4% annualised revenue growth over the past five years.